Vaccination boosts adult immunity to varicella zoster virus

Weir, Erica
August 2005
CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p249
Academic Journal
Highlights the results of a study which provides evidence of the effectiveness of an investigational, highly potent vaccine against the varicella zoster virus in reducing the risk and severity of zoster and post-herpetic neuralgia among healthy adults aged 60 years or older. Characteristics of the vaccine; Relationship between age and the risk of herpes zoster; Diagnostic approaches to varicella zoster infection.


Related Articles

  • Take steps to keep horses healthy.  // High Plains Journal;5/12/2014, Vol. 132 Issue 19, p18B 

    The article offers tips on how to keep the horses healthy and to keep them away from the Equine Herpesvirus Myeloencephalopathy (EHM) including calling the veterinarian when the temperature of the horse is 10.5 F, giving vaccines, and preventing them from getting in contact with contaminated items.

  • Nucleotide Sequences that Distinguish Oka Vaccine from Parental Oka and Other Varicella-Zoster... Argaw, Takele; Cohen, Jeffrey I.; Klutch, Michael; Lekstrom, Kristen; Yoshikawa, Tetsushi; Asano, Yoshizo; Krause, Philip R. // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p1153 

    Identifies nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. Predicted difference in amino acid sequences; Stability of nucleotide changes identified in Oka vaccine viruses after passage in human subjects; Factors attributing to the...

  • Vaccine Approved for Shingles in Older People.  // FDA Consumer;Sep/Oct2006, Vol. 40 Issue 5, p38 

    The article offers information on Zostavax, a vaccine that could reduce the risk of shingles in older people. Shingles is a disease caused by the varicella-zoster virus, the same virus that causes chickenpox. The vaccine not only prevented approximately half of the cases, but also slightly...

  • Herpesvirus Vaccines: An Update. Jennings, R.; Green, T.; Kinghorn, G.R. // BioDrugs;1998, Vol. 10 Issue 4, p257 

    The development of vaccines against the herpesviruses has major public health importance because of the wide spectrum of associated clinical disease with this virus in both immunocompetent and immunocompromised populations. Because these viruses establish latent infections capable of subsequent...

  • Call to use herpes zoster vaccine in older people.  // Pulse;5/5/2010, Vol. 70 Issue 15, p9 

    The article reports on the result of a study made by U.S. researchers which revealed that herpes zoster vaccine should be routinely used to protect older people from shingles.

  • Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Brisson, Marc; Pellissier, James M.; Levin, Myron J. // Clinical Infectious Diseases;12/1/2007, Vol. 45 Issue 11, p1527 

    A letter to the editor is presented in response to the study by M. B. Rothberg and colleagues which examines the cost effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia (PHN).

  • Varicella zoster vaccine worth the cost?  // PharmacoEconomics & Outcomes News;10/7/2006, Issue 513, p5 

    The article discusses research on the cost effectiveness of a varicella zoster virus live vaccine, reference to a study by J. Hornberger and colleagues, published in the September 5, 2006 issue of the journal "Annals of Internal Medicine." The quality-adjusted life survival of patients who were...

  • Vaccines under study.  // Dermatology Times;Feb96, Vol. 17 Issue 2, p51 

    Presents an abstract of an article dealing with the study of vaccines for a number of conditions including herpes, melanoma and AIDS, published in `Men's Health,' January/February 1996. Absence of research on an AIDS vaccine in the United States.

  • Antiviral vaccine may reduce genital herpes episodes, help prevent spread.  // Modern Medicine;Apr94, Vol. 62 Issue 4, p31 

    Reports on the results of a study assessing the effectiveness of a new vaccine in reducing the rate of genital herpes episodes. Study of 98 patients with recurring genital herpes; Recombinant HSV-2 glycoproteins contained in the vaccine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics